Safety analysis of fidaxomicin in comparison with oral vancomycin for clostridium difficile infections

Clinical Infectious Diseases

Volumn 55, Issue SUPPL.2, 2012, Pages

  Weiss, Karl ^a   Allgren, Robin L ^b   Sellers, Sarah ^c  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b Breakthrough Bio Development   (United States)

^c Q Vigilance   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIDAXOMICIN; VANCOMYCIN;

ANEMIA; ANTIBIOTIC THERAPY; CLOSTRIDIUM DIFFICILE INFECTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; HUMAN; LARGE INTESTINE PERFORATION; LEUKOPENIA; MEGACOLON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; TORSADE DES POINTES;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; DOGS; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; HUMANS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84863681880     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis390     Document Type: Review

References (23)

1. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978; 298:531-4. (Pubitemid 8295586)
2. Tedesco FL, Barton RW, Alpers DH. Clindamycin-associated colitis: a prospective study. Ann Intern Med 1974; 81:429-33.
3. McDonald LC, Owings M, Jernigan DB. Clostridium difficile in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006; 12:409-15.
4. Kyne L, Hamel MB, Polavaram L, Kelly CP. Health-care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002; 34:346-53. (Pubitemid 34062235)
5. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multiinstitutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-9. (Pubitemid 41770165)
6. Zilberberg MA, Shorr AF, Kollef M. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States 2000-2005. Emerg Infect Dis 2008; 14:929-31. (Pubitemid 351838602)
7. Browne RA, Fekety R Jr, Silva J, Boyd DI, Work CO, Abrams GD. The protective effect of vancomycin on clindamycin-induced colitis in hamsters. Johns Hopkins Med J 1977; 141:183-92. (Pubitemid 8206325)
8. Bartlett JG. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin Infect Dis 2008; 46:1489-92. (Pubitemid 351706727)
9. Gerding DN. Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection? Clin Infect Dis 1997; 25(Suppl 2):S206-10.
10. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea stratified by disease severity. Clin Infect Dis 2007; 45:302-7. (Pubitemid 47101025)
11. Wenisch C, Parschalk B, Hasenhündl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22:813-8. (Pubitemid 26255600)
12. Louie TJ, Miller MA, Mullane KM, et al. OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422-31.
13. Anti-Infective Drugs Advisory Committee. Dificid™ (fidaxomicin tablets) for the treatment of Clostridium difficile infection (CDI), also known as Clostridium difficile-associated diarrhea (CDAD), and for reducing the risk of recurrence when used for treatment of initial CDI. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/Anti-InfectiveDrugsAdvisory Committee/UCM249354.pdf. Accessed 11 November 2011.
14. Shue YK, Sears PS, Shange S, et al. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother 2008; 52:1391-5. (Pubitemid 351522003)
15. Louie T, Miller M, Donskey C, Mullane K, Goldstein EJC. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009; 53:223-8.
16. Gorbach S, Weiss K, Sears P, Pullman J. Safety of fidaxomicin versus vancomycin in treatment of Clostridium difficile infection [poster L1-1640]. In: Program and abstracts of the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: ICAAC, 2009.
17. Aradhyula S, Manian FA, Hafidh SA, Bhutto SS, Alpert MA. Significant absorption of oral vancomycin in a patient with Clostridium difficile colitis and normal renal function. South Med J 2006; 99:518-20. (Pubitemid 43804523)
18. Osawa R, Kaka AS. Maculopapular rash induced by oral vancomycin. Clin Infect Dis 2008; 47:860-61.
19. Duffy LF, Daum F, Fisher SE, et al. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology 1985; 88:681-4. (Pubitemid 15130655)
20. McGrath NM, Kent-Smith B, Sharp DM. Reversible optic neuropathy due to metronidazole. Clin Experiment Ophthalmol 2007; 35:585-6. (Pubitemid 47337979)
21. Owens RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial- associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46(Suppl 1):S19-31. (Pubitemid 351323662)
22. Weiss K, Boisvert A, Chagnon M, et al. Multipronged intervention strategy to control an outbreak of Clostridium difficile infection (CDI) and its impact on the rates of CDI from 2002 to 2007. Infect Control Hosp Epidemiol 2009; 30:156-62.
23. ViroPharma Inc. Vancocin HCl capsules (vancomycin hydrochloride capsules, USP) [prescribing information]. Available at: http://www. vancocin.com/~/media/ Vancocin/Files/Vancocin-PI.ashx. Accessed 14 November 2011.